Abstract | Occlusive arterial disease is a leading cause of morbidity and mortality worldwide. Aside from balloon angioplasty, bypass graft surgery is the most commonly performed revascularization technique for occlusive arterial disease. Coronary artery bypass graft surgery is performed in patients with left main coronary artery disease and three-vessel coronary disease, whereas peripheral artery bypass graft surgery is used to treat patients with late-stage peripheral artery occlusive disease. The great saphenous veins are commonly used conduits for surgical revascularization; however, they are associated with a high failure rate. Therefore, preservation of vein graft patency is essential for long-term surgical success. With the exception of 'no-touch' techniques and lipid-lowering and antiplatelet (aspirin) therapy, no intervention has hitherto unequivocally proven to be clinically effective in preventing vein graft failure. In this Review, we describe both preclinical and clinical studies evaluating the pathophysiology underlying vein graft failure, and the latest therapeutic options to improve patency for both coronary and peripheral grafts. NATURE REVIEWS | CARDIOLOGY VOLUME 13 | AUGUST 2016 | 451
Occlusive arterial disease is a leading cause of mortal ity globally owing in part to a continually ageing popu lation and shifting demographics. Besides balloon angio plasty, bypass graft surgery is the most commonly performed revascularization strategy in patients with occlusive arterial disease. Coronary artery bypass graft (CABG) surgery is the standard of care for patients with left main coronary artery disease (CAD) and three vessel CAD
, whereas peripheral artery bypass grafting (PABG) surgery is performed in patients with latestage peripheral artery occlusive disease (PAOD
1-4 . The internal mammary artery is the graft of choice for revascularization of the left anterior descend ing coronary artery. However, veins (almost exclusively the great saphenous vein) remain the most commonly used conduits, especially for PABG surgery, owing to availability and length 5 (FIG. 1a) .
Adaptation of vein grafts to their new arterial environ ment is characterized by structural vessel wall remodelling and intimal thickening. The appearance of intimal hyperplasia after vein graft surgery was first described by the Nobel prizewinning surgeon Alexis Carrel more than a century ago 6 . Moderate intimal hyperplasia formation is necessary for proper arterial ization and longterm graft patency. However, why some grafts stop remodelling after arterial ization while others progress to a clinical stenosis is unknown. Patency rates of vein grafts diminish from 98% immedi ately after surgery to <88% within the first month postsurgery owing to acute thrombosis 5 . Intimal hyperplasia, athero sclerosis, and rupture of plaques formed in the vein grafts result in an overall patency of 60% after 10 years 3, 7, 8 (FIG. 1b,c) . Risk factors associated with vein graft failure (VGF) include dia betes mellitus 9 , hypercholesterol aemia 10, 11 , chronic kid ney disease 12 , age, ethnicity, and sex [13] [14] [15] . Several factors associated with graft surgery are also thought to predict VGF, including increased diameter and poor quality of the vein (such as those affected by preexisting medial hypertrophy and intimal hyperplasia 16, 17 ), outflow area of the vein, the location of the artery distal to the occlu sion where the bypass will be attached, as well as sur gical handling of the vein graft during harvesting and when making the anastomosis 18 . VGF can be observed in asymptomatic patients, but can also cause symptoms of ischaemia, depending on the extent of the supplied territory, the presence of native artery disease, and the function of other grafts and collaterals.
The most obvious difference between coronary artery grafts and peripheral grafts is the anatomical location. The length of the grafts and the blood flow and haemo dynamic patterns differ between the locations. However, risk factors, patency rates, and the cellular and molecular processes underlying the pathophysiology of VGF are similar between both graft types. The similarities and differences between CABG surgery and PABG surgery are listed in TABLE 1. At present, statins and antiplatelet agents (specifically, aspirin) are the only medications recommended by the ESC and the ACC Foundation/AHA Task Force for the prevention of VGF 4, [19] [20] [21] . Despite numerous preclinical studies on potential new targets and therapies for the prevention of VGF, an unequivocally effective treatment has not been found 3, 22 . Gene therapy is an attractive option, because graft conduits can be treated ex vivo 22 . In this Review, we discuss the pathophysiological mech anisms underlying the development of VGF, including the cellular and molecular processes involved in vein graft remodelling and intimal hyperplasia formation, and summarize potential therapeutic options that can improve patency based on data from both preclinical studies and the latest clinical trials.
Pathophysiology of vein grafting
Preclinical imaging studies using in vivo models have enabled researchers to construct a timeline of the events that begins with harvesting of the vein grafts and ends with VGF (FIG. 2) . Immediately after harvest ing, venous conduits undergo a period of ischaemia and reper fusion after engraftment, resulting in endothelial cell and smooth muscle cell (SMC) damage 23 . In situ saphenous vein grafts used in PABG surgery are not susceptible to ischaemia, because the vasa vasorae are still intact. The temporary closure of the lumen and reperfusion in these grafts cause damage to the vessel wall, while engraftment in the arterial circulation increases flow and longitudinal and circumferential shear stress, resulting in additional damage to SMCs and the extracellular matrix (ECM) 23, 24 . Platelets and fibrin are deposited, and circulating leuko cytes attach and infiltrate the vessel wall. Growth factors are sub sequently released from platelets, macro phages, and SMCs, leading to increased prolifer ation and migration of SMCs to the intima. Uncontrolled SMC prolifer ation, extensive ECM deposition, and the influx of macrophages all contribute to intimal hyperplasia within the vessel wall. Under hypercholesterolaemic conditions, increased uptake of lipids promotes foam cell formation. Macrophage apoptosis, and subsequent necrotic core formation and intraplaque haemorrhage, further accelerate the process of VGF by forming unstable atherosclerotic lesions 25, 26 .
De-endothelialization and thrombosis
During a bypass procedure, most venous conduits undergo a period of ischaemia followed by reper fusion, resulting in the generation of damage associated molecu lar patterns (DAMPs) and reactive oxygen species (ROS). Together with the damage caused by graft handling and distension during the high pressure check for leakage, ischaemia-reperfusion injury increases oxida tive stress and cytotoxic activation, which culmin ates in loss of endothelial cells and SMCs [27] [28] [29] . Endothelial cells become activated and express inter cellular adhesion molecule 1, vascular cell adhesion protein, selectins, thrombomodulin, and growth fac tors. Some endothelial cells might experience apop tosis, increased blebbing, and vacuolization of Golgi and rough endoplasmatic reticulum, as observed with electron microscopy [30] [31] [32] . Reduced endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) produc tion in the damaged endothelium results in impaired vasorelaxation 33 . In porcine venous grafts, the increase in superoxide production was associated with reduced synthesis of NO and decreased superoxide dismutase activity 34 . Increased oxidative stress and endothelial apoptosis, and the subsequent endothelial damage seen in veins (but not in arterial conduits), contribute to the unfavourable patency rates of vein grafts observed in experimental models [34] [35] [36] . As a result of endothelial denudation, the under lying ECM proteins (for example, collagen, elastin, and proteoglycans) become exposed to the circulation, thereby promoting platelet and fibrin deposition on the thrombo genic luminal surface. Tissue factor proteins become available to initiate thrombin formation, and impaired NO and prostacyclin production in the venous conduits further enhance platelet aggregation 28 . Platelets generate a number of thrombogenic, chemotactic, and vasoconstricting substances, including plateletderived growth factor (PDGF), transforming growth factorβ (TGFβ), fibrinogen, fibronectin, and von Willebrand factor 28 . Activated platelets express adhesion molecules, such as Pselectin and Eselectin, and bind circulating leukocytes, which in turn attach to and infiltrate the vessel wall 37 . The CD40 ligand, which has both pro thrombotic and proinflammatory activity, is exposed and excreted by activated platelets, further accelerating the thrombogenic process 38 . The deposition and sub sequent resolution of fibrin is tightly regulated through the thrombogenic and fibrinolytic pathways and have important roles in the onset of intimal hyperplasia formation 39 . Targets to improve endothelial function include endothelin1, eNOS, and NADPH oxidase, which can all influence haemodynamics and intimal hyperplasia formation via increasing NO or inhibiting superoxide production [40] [41] [42] .
Key points
• Thrombosis, constrictive remodelling, intimal hyperplasia, and unstable atherosclerotic lesions are the critical mechanisms contributing to vein graft failure • Factors associated with the surgical procedure of bypass grafting, such as vein graft harvesting and handling, and the size and condition of the conduit and target vessel, determine long-term patency • Experimental models have shown that inhibiting endothelial cell damage, smooth muscle migration and proliferation, and the inflammatory response contribute to the prevention of vein graft failure • Lipid-lowering therapy, antiplatelet therapy, and the 'no-touch' technique during surgery are clinically proven to prevent vein graft failure • New therapies to prevent vein graft failure, such as gene therapy and external stenting, are promising and require further study • Balloon angioplasty and medical therapy are the preferred revascularization strategies for uncomplicated stenotic grafts, whereas redo graft surgery might be the preferred option for old or diffusely diseased venous grafts
Re-endothelialization
Restoration of the endothelial monolayer begins rapidly after initial damage. Proliferating endothelial cells can be seen as early as 3 days after vein graft surgery in experi mental models 31, 32 . In these models, the endothelial lining remains largely intact 4 weeks after the surgery 23, 32, 35, 43 . The duration of the reendothelialization process in humans is likely to be longer, although the exact time frame is not known and will depend on the length of the vein graft segment used 44 . Murine and human pro genitor cells derived from bone marrow and the adventitia have been shown to contribute to the reendothelialization process [45] [46] [47] [48] . The homing of these progenitor cells is thought to be integrin β 3 dependent 49, 50 , and is directed by inflammatorytype macrophages 51 . In addition, inducible nitric oxide synthase can enhance endo thelial progenitor cell attachment and differentiation 52 . The origin of venous graft endothelial cells in humans is still unclear; however, human allograft endothelial cells were found to be derived from both host and donor cells 53 . Endothelial cells in mature human vein grafts display endotheliumdependent relaxation, and thus are seem ingly functional 44 . However, how nonhost endothelial cells affect the functioning of the endothelium in the graft is still unknown. Results from preclinical studies have thus far shown that enhanced reendothelialization is beneficial in preventing VGF 44 , but so far no thera pies exist to facilitate this process. The promotion of endothelial progenitor cell homing could be a potential future therapeutic target for VGF.
Vein graft arterialization
In 1964, Sziliagyi and colleagues first suggested that a vein needs to undergo a ≥50% increase in dimen sion to adapt to the increased pressure in the arterial circulation 54 . Although this initial adaptation is neces sary for veins to acquire an arterylike structure, this process can also lead to substantial VGF. Arterialization of venous bypass grafts involves processes such as inti mal hyperplasia, geometric remodelling, wall stiffening, and inflammation 24 . Arterial and venous blood vessels have a similar struc ture made up of three distinct layers: the adventitia, the media, and the intima. Compared with arteries, cellu lar and fibrous components within veins are consider ably limited in number and size. Furthermore, veins con tain valves to prevent blood reflux. The venous wall is highly adapted for continuous changes in blood volume, but the pressure and flow in the venous system are low compared with the arterial system. Interpositioning of a vein into a high pressure and flow arterial environ ment results in morphological and geometrical changes to the venous conduit 55 . Intimal hyperplasia and vessel wall thickening are the direct results of SMCs and ECM expansion induced by increased pressure, shear stress, and inflammatory responses 3 . For example, shear stress in the saphenous vein rises from 0-4 dynes/cm 2 to up to 30 dynes/cm 2 after engraftment 44 . The geometrical adaptation of the vein is thought to be primarily mediated through the endothelium, as it is sensitive to haemodynamic stresses 3, 56, 57 . The three geometric parameters that are generally used to determine the mode of remodelling are lumen calibre, wall thickness, and lesion area. The haemodynamic forces, together with the geometric parameters, main tain the vessel in a state of maximum efficiency for the transport of blood. According to the law of Poiseuille, circum ferential, longitudinal, and radial stress result in dilatation of the vessel 58 . The venous conduit in the arterial system is thought to direct stress in nine dif ferent directions 59 . Constrictive remodelling or loss of lumen calibre is associ ated with low levels of shear stress 24, 60 . Interestingly, Zilla et al. demonstrated that the saphenous vein displays different degrees of remodel ling in coro nary bypasses compared with infrainguinal bypasses, owing to different flow patterns, and stress and shear force 61 . They also showed that coronary grafts in a nonhuman primate model express a high degree of lumen loss and intimal hyperplasia formation, whereas infrainguinal grafts display increased dilatation 61 . Tomographic intravascular ultrasonography (IVUS) enables the visualization of the full circumference of the vessels, thus allowing evaluation of early geometric vascular remodelling in vivo 62, 63 . Early wall thickening and expansive remodelling of vein grafts occurs within the first few weeks after implantation and stabilizes after 6 months, as observed with IVUS 3, 64 . Expansive or positive outward remodelling is believed to delay the development of lumen loss, although this is frequently inadequate for the preservation of luminal size in the long term [65] [66] [67] . In the first year after surgery, a consider able portion of the vein graft shows constrictive or inward remodelling, a compensatory response to vessel wall thickening 68 . Unlimited expansive remodelling and inward remodelling are detrimental to vein graft arterialization. Gasper et al. demonstrated that early
Box 1 | Coronary artery disease
• Coronary artery disease (CAD) is the most common type of heart disease, and occurs when atherosclerotic lesions narrow the coronary arteries, leading directly to reduced oxygenation of the myocardium. Symptoms of CAD include chest pain (angina) or myocardial infarction • Treatment options for CAD include lifestyle changes, medication, percutaneous coronary intervention with or without stenting, or coronary artery bypass graft (CABG) surgery • Conduit choice in CABG surgery depends on many patient-specific factors, including location and severity of the target coronary artery stenosis, comorbidities, estimated life expectancy, number of bypasses needed, and availability of graft material • When revascularizing the left anterior descending coronary artery, the left internal mammary artery (IMA) is the preferred graft for CABG surgery 4, 19 . Alternatives include the right IMA, the radial artery, right gastroepiploic artery, and the saphenous vein • The use of the saphenous vein graft is advantageous compared with arterial conduits for several reasons: they are easily harvested, easily handled when making anastomoses, are not influenced by vasospasm, do not increase the risk of sternal wound infection, and are readily available in most patients • In general, arterial conduits are considered to have higher patency rates than vein grafts 296, 297 . Radial artery patency is lower than that of IMA grafts and more dependent on the severity of the target coronary artery stenosis 298 . Furthermore, vasospasm can also occur, owing to the muscular nature of the radial artery wall • Inconsistent results have been reported for patency rates in saphenous vein grafts and radial artery grafts [299] [300] [301] remodelling was predictive of future VGF, and suggested that patients at risk should be closely monitored 69 . Use of an external support that could prevent shear stress and decrease wall tension and thereby prevent SMC prolifer ation, outward remodelling, and intimal hyperplasia formation, has proven to be a potential strategy in both human tissue cultures and experimental models [70] [71] [72] [73] [74] , and will be discussed in detail below.
Intimal hyperplasia formation
Smooth muscle cells. The intima and media of veins consist of several cell layers. During harvesting and after engraftment, SMCs within these layers undergo ischaemia and apoptosis 23, 31 . Matrix turnover and the prolifer ation, migration, and death of SMCs are impor tant components in intimal hyperplasia formation. During migration from the media to the intima, or from the anastomosed artery towards the intima of the graft, SMCs change from a quies cent contractile phenotype to a dediffer entiated, proliferating, or synthetic pheno type [75] [76] [77] . Smooth muscle like cells derived from adven titial fibroblasts also contribute to intimal hyperplasia formation 78, 79 . These adventitial fibroblasts are highly proliferative and produce greater levels of superoxide compared with SMCs, owing to reduced activity of super oxide dismutase 34 . Veins do not contain substantial elastic laminae, and consequently, fibroblasts in the adven titia can easily migrate to the intima in veins. However, intact elastic laminae within arteries prevent transmural migration, which contributes to the difference in intimal hyperplasia formation between arterial and vein grafts. Adventitial and bonemarrowderived progenitor cells are also involved in vein graft intimal hyperplasia 47, [80] [81] [82] [83] [84] [85] . Interestingly, bonemarrowderived cells are reported to express a SMC phenotype, but do not fully acquire the definitive SMC lineage 86 . The CXCchemokine ligand CXCL12 (also known as stromal cellderived factor 1)/CXCR4 (also known as platelet factor 4) axis is essential for homing of bonemarrowderived cells. Vein grafting in Cxcr4 −/− mice resulted in reduced vein graft thickening 87 . Most bone marrow cells express fibroblast specific protein 1 (FSP1), which lead the cells to home in a (platelet derived) CXCL12dependent manner. Knockdown of FSP1 in bone marrow cells prevented the formation of intimal hyperplasia 88 . SMCs and other cells in the vein grafts express numerous growth factors such as vascular endothelial growth factor (VEGF), PDGF, basic fibroblastic growth factor (bFGF), TGFβ, and endothelin1, which are major stimulators of SMC migration, proliferation, and apoptosis [89] [90] [91] [92] [93] . Targeting these growth factor receptors in vivo interferes with intimal growth [93] [94] [95] [96] [97] [98] . The mitogen activated protein kinase (MAPK), extracellular signal regulated kinase (ERK), and Akt (also known as RACα serine/threonineprotein kinase) signalling pathways are critical for the regulation of cell cycle progression [99] [100] [101] , and can also directly influence SMCs and intimal hyper plasia formation 101, 102 . The expression of growth factors and signal transduction pathway factors varies between arterial and venous grafts [103] [104] [105] . For example, higher MAPK and Akt activity levels were observed in venous SMCs compared with arterial SMCs 106 , which might contribute to the low patency of venous grafts.
Extracellular matrix.
Remodelled vein grafts contain a large repertoire of matrix metalloproteinases (MMPs), predominantly MMP2 and MMP9 . MMPs degrade collagen and other components of the ECM in the vessel wall. Doxycycline, a general MMP inhibitor, suppressed intimal hyperplasia formation in murine vein grafts 109 . Furthermore, specific gene silencing of MMP2 and MMP9 in cultured saphenous vein SMCs resulted in decreased cell migration through a Matrigel barrier 111 . Interestingly, vein grafting in mice deficient in MMP9 did not alter intimal hyperplasia growth compared with control mice; however, MMP9deficient mice did show an increase in collagen content 112 . Endogenous tissue inhibitors of MMPs (TIMPs) have also been the focus of much research related to vein grafts. Overexpression of TIMP1, 2, and 3 in various vein graft models resulted in inhibition of MMP activity and a reduction in SMC migration and proliferation, thereby preventing intimal hyperplasia formation 25, [113] [114] [115] [116] [117] . While MMPs regulate ECM breakdown, TGFβ is known to enhance matrix depositions. During early stages of vein graft adaptation, upregulation of TGFβ is associated with increased mRNA expression of C-C motif chemokine (CCL) 2, collagen I, and col lagen III 92, 118 . Abrogation of TGFβ signalling in rats resulted in decreased intimal hyperplasia and increased MMP expression 98 . In addition, SMCs also generate hyaluronic acid, a glycosaminoglycan and an important constituent of the ECM. Human saphenous vein grafts are characterized by increased deposition of hyaluronic acid and elevated expression levels of all three isoforms of hyaluronic acid synthase 119 .
Box 2 | Peripheral artery occlusive disease
• Peripheral arterial occlusive disease (PAOD) is a common circulatory condition characterized by narrowing of peripheral arteries owing to atherosclerosis, which subsequently reduces blood flow to the lower limbs • Many patients with PAOD are asymptomatic (Fontaine I) 302 . The most frequent presentation of PAOD is intermittent claudication, defined as reproducible lower extremity muscular pain induced by exercise and relieved by standing still (Fontaine II) 303 • Several treatment options are available for symptomatic PAOD, including exercise therapy and pharmacotherapy. In case of ischaemic rest pain (Fontaine III), ulceration or gangrene (Fontaine IV), and when conservative treatments are unsuccessful, surgical treatment options are required • Invasive endovascular treatment, such as balloon angioplasty, is recommended for these patients. Balloon angioplasty combined with stent implantation improves patency rates compared with balloon angioplasty alone • Owing to the length or the location of the occlusion, balloon angioplasty is not always a treatment option. In such situations, bypass surgery is the preferred treatment strategy • Autologous veins (such as the saphenous vein) are the first conduits of choice • Alternative conduits include polytetrafluoroethylene, Dacron grafts, or modified decellularized umbilical cords • Bypass surgery is possible only when the blood vessel is sufficiently patent distal to the occlusion • When bypass surgery is technically impossible, or in case of critical limb ischaemia with extensive necrosis or infectious gangrene, amputation is the last treatment option
Increased expression of members of the plasminogen activation system has been observed in human failed vein grafts 120, 121 . In addition to their role in fibrinolysis and proteolysis, plasminogen activators (PAs) can also exert their activity on SMCs and the ECM. Components of the ECM, such as laminin and fibronectin, can be cleaved by plasmin that is formed from plasminogen by plasminogen activators, resulting in activation of cell surface receptors and MMPs 122 . The plasminogen activation system consists of two main PAs: urokinase type PA (uPA) and tissuetype PA (tPA). uPA is essen tial in extracellular proteolysis, cell migration, and matrix remodelling, whereas tPA is mainly involved in fibrinolysis 123 . Overexpression of tPA in porcine vein grafts resulted in reduction of early vein graft throm bosis 124 . Plasminogen activator inhibitor 1 (PAI1), through its regulation of PA activity, has been shown to regulate proliferation, migration, and apoptosis of SMCs and endothelial cells 125 . Intimal hyperplasia was enhanced in PAI1deficient mice owing to increased thrombin activity 126 .
Given that inhibition of either PAs or MMPs has been shown to reduce intimal hyperplasia in vivo, a hybrid protein consisting of TIMP1 and the receptor binding aminoterminal fragment (ATF) of urokinase was con structed to more efficiently inhibit protease activity locally 127 . This construct enhanced the inhib itory effect of murine vein graft intimal hyperplasia and preser vation of luminal area compared with their individ ual counterparts 128 . A further construct was created by adding bovine pancreas trypsin inhibitor (BPTI), a potent protease inhibitor that can inhibit both MMP and plasmin activity at the cell surface, to the existing TIMP1.ATF construct, which resulted in retardation of intimal hyperplasia and outward remodelling 129 . Adenoviral overexpression of the hybrid protein ATF. BPTI also reduced intimal hyperplasia formation in human saphenous vein grafts in vitro 130 .
Inflammatory mediators. Inflammatory mediators are critical in all phases of vein graft development 131, 132 .
Early afterengraftment DAMPs such as proteoglycans, heat shock proteins, and biglycan are among the first mediators of inflammation 133, 134 . Endogenous DAMPs activate Tolllike receptors (TLRs) that are expressed by endothelial cells, SMCs, and macrophages in the vein grafts 134, 135 . Genetic deletion and RNA silencing of TLR4 in a murine model of VGF reduced outward remodel ling and intimal hyperplasia formation as a result of a suppressed inflammatory response 134 . Interestingly, carotid ligation in TLR4deficient mice showed outward remodelling without intimal hyperplasia formation in the nonligated artery 136 , suggesting that TLR4 affects vascular remodelling independently of intimal hyper plasia formation; TLR4, therefore, might have a role in haemodynamic adaptations.
Other TLR4 ligands include oxidized LDL (oxLDL) and phosphorylcholine, both known for their role in the development of atherosclerosis. The role of oxLDL and subsequent lipid retention in VGF has been observed, Nature Reviews | Cardiology especially under hypercholesterolaemic conditions 23 . Low levels of natural antibodies against phosphoryl choline in humans are associated with VGF, whereas passive immunization with antiphosphorylcholine antibodies prevents vein graft atherosclerosis in a hypercholesterolaemic murine model 137, 138 . With the exception of TLR3, all TLRs signal via the myeloid differentiation primary response protein 88 (MYD88) pathway, which activates nuclear factor κlightchain enhancer of activated B cells (NFĸB) and results in induction of proinflammatory cytokines 139 . NFĸB is one of the most important transcription factors for promotion of inflammatory responses in vein graft remodelling. In experimental models, strategies to inhibit NFκB resulted in attenuation of intimal hyper plasia formation by reducing inflammation [140] [141] [142] . NFĸB can activate the cytokines CCL2 and tumour necrosis factor α (TNFα), both of which have been extensively studied in VGF 143, 144 . A dominant receptor antagonist of CCL2, 7NDMCP1, reduced vein graft athero sclerosis and monocyte invasion in mice on a hyper cholesterolaemic diet 145 . Furthermore, RNA silencing of the CCL2 receptor, CCR2, resulted in reduced SMC proliferation and migration in vitro and abrogation of intimal hyperplasia in vivo 145 . As a result of the early induction of TLRs, TNFα is upregulated in early vein graft develop ment. In TNF receptor1deficient mice, vein graft intimal hyperplasia was reduced as a result of decreased CCL2 expression and SMC proliferation 146 . In addition, TNF receptor2deficient mice showed abrogated vein graft intimal hyperplasia owing to endothelial cell apoptosis 147 . These studies illustrate the various mechanisms that can contribute to reducing vein graft intimal hyperplasia.
In general, cytokines are proinflammatory mediators that induce cell remodelling by activating inflammatory cells, SMCs, and endothelial cells 132, [148] [149] [150] . In their role as patternrecognition receptors, TLRs are central in the induction of inflammatory responses, and can acti vate inflammatory cells of both the innate and adaptive immune system, in addition to activating complement factors. Like TLRs, complement factors are present in the vein graft wall, enhancing crosstalk between these com ponents of the innate immune system. Complement fac tors are expressed in both genes and proteins in murine grafts, indicating that they are produced by the vessel wall as an extrahepatic source 116, 151 . Interference with the key complement factor C3, and alternative pathway com ponent C1 and C5, resulted in reduced intimal hyper plasia by preventing endothelial cell damage, inhibiting SMC proliferation, and reducing inflammatory signal ling in murine vein grafts [151] [152] [153] . Complement factors are thus very promising targets for the treatment of VGF in humans. An exploratory analysis of the PRIMOCABG I and II trials 154 reported that intravenous administration of pexelizumab, an antibody against complement fac tor C5, reduced mortality in highrisk surgical patients undergoing CABG surgery.
Inflammatory cells that invade the vein graft reside in specific locations in the vessel wall. Neutrophils are found mainly in the fibrin layer that is formed on the deendothelialized lumen during early onset of intimal hyperplasia formation 155, 156 . Neutrophils produce a wide array of angiogenic growth factors and proteases such as MMP9, but their main role is to regulate neighbour ing inflammatory cells such as macrophages . Macro phages comprise the vast majority of inflammatory cells in the intima and media 158 . Monocytes roll, attach, and invade the graft via the lumen, but can also enter via neovessels in the adventitia. Under the influence of macrophage colony stimulating factor, monocytes become macrophages, which produce and release a broad array of cytokines and growth factors. In the case of vein grafts, SMCs are the predominant target of these macrophages 159 . In rabbit and murine vein grafts, indirect inhibition of macrophages, for exam ple by target ing macrophage activating factors, was successful in preventing the inflammatory response and VGF 141, 160, 161 . The adventitia, made up of loose connective tissue, small neovessels, and perivascular fat, is an important source of inflammatory cells; dendritic cells, T and B cells, mast cells, and natural killer (NK) cells seem to have a preference for the adventitia 162 . Dendritic cells originate from Ly6C lo monocytes and are special ized in presenting antigens to T cells 163 . Dendritic cells can also activate T cells by expressing costimulatory factors, and can thereby regulate vein graft remodel ling 162, 164 . Mast cells are large granular cells that can actively release granules containing tryptase, chymase, and histamine. Aside from the classical activation route of binding to immunoglobin E 165 , mast cells can also be activated via cytokines (TNFα, IL1) and complement factors (C3a and C5a) 166 . Vein grafts are rapidly repopu lated with mast cells after surgery; both resting and acti vated mast cells can be found within the peri vascular region in murine vein grafts 153, 167 . Mast cells have been linked to the development of atherosclerosis, but are mostly thought to be effector cells of plaque rupture and erosion 168, 169 . Local activation of mast cells resulted in increased unstable lesions and vein graft rupture 153 . Furthermore, vein grafts in mast celldeficient mice show reduced intimal hyperplasia 153 . Also present in the adventitia are NK cells, a small subset of lymphocytes initially described for their 'natural' capacity to kill cells depending on the expression of activating and inhib iting NK cell receptors specific for MHC class I mol ecules. NK cells can be activated by secretion of lytic granules containing perforin and granzymes, but also by secretion of various cytokines 170 . Limited numbers of NK cells are found in the perivascular region of vein grafts 171 . BALB/c mice lack crucial NK cell genes of the Ly49 receptor family, resulting in reduced NK cell function. Vein graft surgery performed in BALB/c mice congenic for the C57BL/6 NK gene region showed a similar degree of intimal hyperplasia compared with C57BL/6 mice, whereas BALB/c mice showed signifi cantly less intimal hyperplasia 171 . This difference was accompanied by a decrease in inflammatory cells and IFNγ expression in the vein graft 171 .
In general, components of the innate immune system are known to accelerate intimal hyperplasia formation and graft failure (FIG. 3) . The role of adaptive immunity is less clear, although both T and B cells have been identified in vein grafts 172 , as well as the crucial T cell costimulatory molecule CD40 (REF. 164 ). Although the role of the adaptive immunity in related vascular dis eases, atherosclerosis, and restenosis has been well estab lished 173, 174 , further studies are needed to investigate the role of T and B cells in VGF.
Atherosclerosis and rupture
Atherosclerotic lesion formation is characteristic of late phase VGF [175] [176] [177] . Human autopsy studies have shown that coronary vein grafts undergo more rapid athero sclerotic lesion development than native arteries 8 . Coronary vein graft atherosclerotic lesions are more concentric and diffuse than native atherosclerotic lesions, and are more susceptible to thrombosis and rupture 26 . In contrast to coronary vein grafts, the morpho logical organization and development of latephase peripheral vein graft lesions have received less attention. Westerband et al. showed that peripheral lesions have a predominance of highly proliferative SMCs 178 . Furthermore, occluded peripheral grafts are associated with high numbers of circulating inflammatory cells 179 . However, to what extent atherosclerosis contributes to latephase stenosis in peripheral grafts is unclear.
Foam cell formation in vein grafts has been observed as early as 1 year after surgery 180 . A necrotic core tends to develop between 2 and 5 years after surgery, and is often accompanied by intraplaque haemorrhage from leaky angiogenic neovessels 7, 180 . Yazdani et al. demonstrated that lesions that form after CABG surgery that have a thin fibrous cap and contain large haemorrhagic necrotic cores have a high frequency of plaque rupture 180 . Furthermore, features of latephase failure, such as necrotic cores, angio genic neovessels, intraplaque haemorrhage and rupture, could be observed in an experimental vein graft model in hypercholesterolaemic mice 25 (FIG. 4) .
The appearance of plaque neovessels and intraplaque haemorrhage are frequently observed in this model (FIG. 5) , whereas they are rarely seen in atherosclerotic Nature Reviews | Cardiology experimental models. Upregulation of TIMP1 resulted in improved lesion stability and decreased plaque rupture 25 . Targeting inflammatory factors such as annexin A5, mast cells, and complement factor C5a in this murine vein graft model is an effective strategy not only to diminish intimal hyperplasia, but also to reduce atherosclerosis and plaque rupture by enhancing lesion stability 153, 160, 181 .
Vein graft handling during surgery When a vein graft is used for coronary revascularization, the surgeon takes into account several technical factors to minimize the risk of early and late VGF. These factors include choosing the optimal site for the distal anastomosis (aiming at a high outflow target area and minimizing the size discrepancy between the vein and the target vessel), and careful measurement of bypass length to prevent kinking or flattening that will lead to turbulent or decreased flow. Although sequential venous grafting has a potential down side of increased risk of proximal stenosis, this technique reduces resistance to graft flow, which might explain the higher patency rates of sequential venous grafts compared with single venous grafts 182 . In general, graft patency of sequential vein grafts is highest when the last distal anasto mosis is made to the coronary artery with the largest runoff. However, appropriate vein harvesting is likely to be at least equally as important in determining vein graft patency.
No-touch technique
During harvesting of the saphenous vein, forceful dilata tion of the vein to alleviate spasm and check for leakage should be avoided, as it can damage the endothelium (FIG. 6) . In 1996, the 'notouch' technique was introduced, whereby the vein is harvested with a pedicle of surround ing tissues, maintaining the vasa vasorae and the nerves in the adventitia 183 . This technique improved shortterm and longterm vein graft patency rates and reduced intimal hyperplasia formation in a randomized, controlled trial performed in 2002 (REFS 184, 185) . Several subsequent trials also showed the beneficial effect of this notouch technique on vein graft patency. In the PATENT SVG trial 186 , the notouch technique led to decreased SMC activation. Samano et al. reported higher patency rates for grafts harvested using the notouch technique compared with veins harvested using the conventional method in a study with a mean followup of 16 years 187 . The veins harvested using the newer technique had a patency rate of 83%, similar to that of left internal thoracic artery patency rates in this study (88%). However, only a limited number of patients (17 and 54 patients, respectively) were evalu ated in these trials. A larger trial to compare the notouch technique to conventional harvesting is currently ongoing in 1,550 patients undergoing CABG surgery, with primary end points of graft patency and mortality at 1 year
188
.
Endoscopic versus open vein harvesting
Minimally invasive or endoscopic techniques for vein harvesting have the potential benefit of diminishing woundrelated complications and reducing post operative pain and morbidity compared with conventional tech niques 189, 190 . The ROOBY trial 191 reported improved 1year graft patency with endoscopic saphenous vein harvesting compared with open harvesting. However, higher rates of VGF and longterm mortality have also been linked with the minimally invasive endoscopic tech nique 192, 193 . Given the discordant results, no consensus has been reached on a goldstandard method for vein harvest ing 194, 195 . The ongoing REGROUP trial 196 aims to deter mine the best technique for vein graft harvesting with regard to reducing major adverse cardiac events. 
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Vein preservation
Extensive handling and desiccation during collection of the saphenous vein can result in spasm and endothelial dam age. Numerous studies have sought to determine the best solution to preserve optimal endothelial function of the harvested vein and, therefore, maintain high graft patency rates. Many studies consistently demonstrate the detrimen tal effects of saline on vascular endothelium, including a study published in 2015 reporting that saline preservation of human saphenous veins led to acute cellular injury 197 . However, no clear consensus exists on whether heparin ized autologous whole blood is superior to saline as a stor age medium 198 . Randomized, controlled trials are needed to compare autologous whole blood with saline for vein graft preservation, and to determine the best time and tem perature for saphenous vein graft storage. Aside from graft preservation fluid, surgical skin markers to orient conduits can also impair physiological function of the vein grafts as they contain methylene blue dye 199 . However, in a study published in 2015, a nontoxic dye alternative to current surgical skin markers called brilliant blue FCF ameliorated vein graft injury in the porcine saphenous vein 200 .
Graft configuration
Three techniques for saphenous vein graft placement have been described: reversed, in situ, and nonreversed translocated vein graft placement. The reversed graft configur ation technique is considered the gold standard method of vein graft placement 201 . By reversing the saphenous vein graft (that is, by connecting the distal end of the graft to the proximal part of the artery and vice versa), the venous valves do not obstruct the arterial blood flow. However, disadvantages are also associated with this technique, including the size mismatch between the narrow distal end of the saphenous vein graft and the larger diseased artery, a shortcoming that is not pres ent in non reversed translocated vein graft placement. In nonreversed saphen ous vein grafts, blood flow is dis rupted owing to the presence of venous valves, whereas in both reversed and nonreversed graft configurations, the saphen ous vein graft is completely removed and thus might be traumatized or twisted and subjected to a period of ischaemia. In situ saphenous vein grafts, used in PABG surgery, do not experience ischaemia owing to preser vation of the vasa vasorae. Previous studies have shown that graft configuration seems to have little influence on patency outcomes [201] [202] [203] .
Preventive strategies Established pharmacology
As previously described, venous segments undergo exten sive endothelial damage during the bypass procedure. The loss of the endothelial cell layer can promote platelet adhe sion and thrombosis 204 . Given that platelet activation and thrombin production have been shown to be the main cause of early VGF, antiplatelet therapy is thought to be beneficial after both CABG and PABG surgery to prevent early vein graft thrombosis (TABLES 2,3) . The first randomized trials on the efficacy of anti platelet and anticoagulant drugs in improving vein graft patency were conducted in the late 1970s [205] [206] [207] . In early trials, no beneficial effects of antiplatelet and anti coagulant drugs were seen on graft patency, prob ably owing to late drug administration (typically ≥3 days after surgery). Subsequent randomized, controlled trials showed that aspirin alone 208 and dual antiplatelet therapy 209 were effective in preventing graft occlusion compared with placebo. These positive results might be associated with administration of the drugs directly before and after surgery, because the thrombotic pro cess begins during the operation when the endothelium becomes damaged.
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Antiplatelet therapy. The ESC recommends lowdose aspirin (75-100 mg per day) for all patients with CAD (class I recommendation, level of evidence A) and PAOD (class I recommendation, level of evidence C) after revascular ization 20, 210 . In the USA, the ACC Foundation/AHA Task Force advises that 100-325 mg per day of aspirin should be administered to patients undergoing CABG surgery, preferably preoperatively, or within 6 h postoperatively to prevent VGF (class I recommendation, level of evidence A) 19 . Similarly, after PABG surgery, patients should receive antiplatelet ther apy indefinitely (class I recommendation, level of evi dence A) 21 . The optimal dosage of aspirin to prevent VGF still needs to be determined.
Several antiplatelet agents have been evaluated for their capacity to prevent VGF, including clopidogrel and ticlopidine, which are both P2Y 12 receptor inhibitors. Although ticlopidine has been reported to be beneficial for graft patency 211, 212 , clopidogrel should be used in prefer ence postoperatively if it is available, as it has fewer adverse effects [213] [214] [215] . Currently, clopidogrel is an accepted alternative in case of aspirin intolerance after CABG sur gery as recommended by the ESC (class I recommenda tion, level of evidence B) 210 , and the ACC Foundation/ AHA Task Force (class IIa recommendation, level of evi dence C) 19 . After PABG surgery, dual antiplatelet therapy with aspirin and clopidogrel is recommended for below knee polytetrafluoroethylene grafting (class IIb recom mendation, level of evidence B) 20 , based on results of the CASPAR trial 216 . However, antiplatelet therapy was bene ficial only after prosthetic bypass grafting, whereas no benefit was observed after autogenous saphenous vein grafting. Therefore, antiplatelet therapy is not routinely recommended for autogenous vein grafts.
Several studies have reported beneficial effects of adding clopidogrel to aspirin therapy for reducing VGF [217] [218] [219] [220] . Currently, dual antiplatelet therapy is recom mended after CABG surgery in patients with acute unstable angina undergoing urgent surgical revascular ization, but to date, not all surgeons prescribe dual ther apy for this patient cohort 19 . The use of dual therapy has not been unequivocally proven to be beneficial for patients undergoing PABG surgery. Nature Reviews | Cardiology Given inconsistent results in the literature, whether the addition of dipyridamole, an anticlotting agent, to aspirin has a beneficial effect on graft patency is still under debate [221] [222] [223] . In a metaanalysis by Bedenis et al., 16 studies comparing the effect of different antiplate let and oral anticoagulant agents on graft patency and limb salvage were reviewed 224 . The investigators con cluded that antiplatelet therapy with aspirin or aspirin plus dipyridamole had a beneficial effect on primary graft patency of PABG surgery compared with placebo or no treatment. However, dual antiplatelet therapy in patients receiving a prosthetic graft, compared with a venous graft, seemed to be more beneficial than mono therapy 225 , suggesting that dipyridamole should be added to aspirin only in the context of prosthetic grafts. Current European guidelines recommend dual anti platelet therapy of aspirin and dipyridamole only after infrainguinal bypass graft surgery, and no distinction is made in graft material 20 . Indobufen, an antiplatelet agent that prevents platelet aggregation by reversibly inhibiting cyclooxygenase, has been investigated as a potential alternative to aspirin 226 . In a crossover study, researchers showed that indobufen was as effective as aspirin in inhibiting platelet aggre gation 226 . Several clinical trials have also shown similar benefits of indobufen and aspirin plus dipyridamole in preventing VGF [227] [228] [229] . Whether indobufen could be con sidered as an alternative treatment for dual antiplatelet therapy is still under investigation. No recommendations have been made in current guidelines regarding the use of indobufen.
Oral anticoagulants. Oral anticoagulants are recom mended after CABG surgery if the patient is considered to be at risk of a thromboembolic event. According to the ESC, anticoagulation should be considered for ≥3 months, with reassessment of stroke risk thereafter (class I recommendation, level of evidence C) 4 . Oral anticoagulants such as vitamin K antagonists, factor Xa inhibitors, or direct thrombin inhibitors can inhibit and even prevent thrombus formation on the luminal surface. At present, a consensus has not been reached regarding the use of oral anticoagulants alone or in addi tion to antiplatelet therapy in the prevention of VGF. Patients undergoing infrainguinal venous graft surgery are more likely to benefit from vitamin K antago nists than from antiplatelet therapy 230 . In the Dutch BOA study 231 , oral anticoagulation seemed to be more effective in preventing VGF, whereas aspirin prevented cases of polytetrafluoroethylene graft occlusions 232 . Furthermore, Johnson et al. demonstrated that addition of warfarin therapy to aspirin therapy did not improve vein graft patency rates 224 .
Lipid-lowering drugs. The ESC recommends statin therapy for patients undergoing CABG surgery (class I recommendation, level of evidence A) with an initial LDLcholesterol goal of <70 mg/dl (<1.8 mmol/l) 210 . In addition, the ACC/AHA guidelines recommend an LDLcholesterol goal of <100 mg/dl and ≥30% lower ing of LDLcholesterol level (class I recommendation, level of evidence C) 19 . Statins are also indicated for all patients undergoing PABG surgery to strive for a tar get LDLcholesterol level of <100 vv mg/dl, and <70 mg/dl for patients with lower extremity PAD at very high risk of ischaemic events (class IIa recommendation, level of evidence B) 21 . The beneficial effect of statin therapy is thought to be based on its inhibitory effects on SMC proliferation and its antiinflammatory effects, which result in decreased intimal hyperplasia formation [233] [234] [235] [236] [237] . Statin therapy was also reported to be protective against death after CABG surgery 231 . Although most studies focus on lowering LDLcholesterol level in these patients, the CASCADE trial 238 showed that HDL levels <40 mg/dl were associ ated with a trend towards increased VGF, suggesting that higher levels of HDL cholesterol might slow the process of VGF.
Emerging preventive strategies
Ticagrelor. The P2Y 12 antagonist ticagrelor was reported to be safe and effective for platelet inhibition in a phase II trial in patients with critical limb ischaemia 239 . Hansson et al. observed a lower overall incidence of major bleed ing complications in patients undergoing CABG surgery treated with ticagrelor compared with clopidogrel 240 . Moreover, compared with clopidogrel, discontinu ing ticagrelor for <24 h before surgery increased the risk of complications, whereas discontinuing ticagre lor 3 or 5 days before peripheral endovascular proce dures showed no differences in complications 241 . The PLATO trial 242 showed that combined ticragrelor and aspirin treatment was superior to combined clopidogrel and aspirin treatment in patients with acute coronary syndrome. The ongoing, prospective TiCAB trial 243 is designed to investigate the efficacy and safety of ticagre lor compared with aspirin in patients undergoing CABG surgery, with the primary end point of cardiovascular death, myocardial infarction, targetvessel revasculari zation, and stroke. Although the use of ticagrelor after CABG surgery has been studied extensively, whether it is beneficial for patients undergoing PABG surgery is not yet known. Nature Reviews | Cardiology a b Direct platelet-receptor inhibitors. Platelets have a major role in the development of CAD, PAOD, and VGF. VGF still occurs despite dual antiplatelet ther apy, probably owing to the complexity of the throm bus formed. Thrombin, a potent platelet agonist that acts via proteaseactivated receptors (PAR), might be a further potential target to prevent thrombus forma tion. Antiplatelet drugs do not affect platelet activation mediated by thrombin 244 , and thus blocking PAR might inhibit VGF.
Several phase II and III trials have been performed to study the efficacy and safety of the PAR1 antago nists vorapaxar and atopaxar 245 . In a phase II study published in 2009, vorapaxar treatment was compared with placebo in patients with CAD undergoing balloon angioplasty. Vorapaxar was well tolerated among treated patients, and did not increase the risk of bleed ing 246 . Investigators in the phase III TRA 2°PTIMI 50 study 247, 248 , a randomized, doubleblind, placebo controlled trial, evaluated the efficacy and longterm safety of vorapaxar in 26,449 patients with previous atherothrombosis. Vorapaxar reduced cardiovascular death, myocardial infarction, or stroke in stable patients with a history of myocardial infarction 247, 248 . The sub sequent TRACER trial 249 reported similar results in patients with nonSTsegment elevation acute coro nary syndrome who were undergoing CABG surgery. Together, these results suggest that vorapaxar might be safe for the prevention CABG surgeryrelated bleeding, but whether vorapaxar can improve vein graft patency in patients undergoing bypass grafting remains to be elucidated.
The safety and efficacy of atopaxar for patients with acute coronary syndromes and chronic CAD have also been evaluated in a phase II trial 250 . The JLANCELOT investigators reported that atopaxar did not increase clinically significant bleeding compared with placebo 250 . Kogushi et al. demonstrated inhibition of SMC prolifer ation in vitro and reduced intimal hyperplasia in vivo with atopaxar 251 . Atopaxar reduced early ischaemia on Holter monitoring without significantly increas ing major or minor bleeding events in patients after an acute coronary event in a phase II trial 252 . A subse quent phase II trial reported more minor bleeding with atopaxar compared with placebo, and numerically, but not significantly, fewer ischaemic events in patients with CAD 253, 254 . Phase III trials are needed to confirm the beneficial effect of direct thrombin inhibitors in preventing VGF.
Inhibition of SMC proliferation and migration. SMC proliferation and migration to the intima is tightly regu lated by growth factors such as VEGF, PDGF, TGFβ, and bFGF. SMC proliferation and migration is necessary for arterialization that occurs in response to injury after bypass surgery. However, excessive SMC stimulation ultimately leads to formation of intimal hyperplasia 255 . Inhibition of SMC proliferation and migration is one of the primary targets for the treatment of VGF. The cyclindependent kinase inhibitor 1B (also known as p27Kip1) has an important role in maintaining SMC quiescence. p27Kip1 reduction led to diminished inti mal hyperplasia formation in experimental vein graft models 256, 257 . Interestingly, a single nucleotide poly morphism in the promoter region of the p27Kip1 gene is associated with peripheral graft patency 252 . Immunosuppressant drugs such as paclitaxel and sirolimus have also been shown to reduce SMCdriven intimal hyperplasia in various experimental mod els [258] [259] [260] . To date, clinical trials to assess the benefit of these antiproliferative drugs for VGF have not yet been performed. However, the use of drugeluting stents (DES) containing paclitaxel or rapamycin to revascular ize failing grafts have been proven beneficial, and is discussed below.
E2F transcription factor oligonucleotide decoys.
Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and, therefore, might prevent intimal hyperplasia formation and VGF. Although experimental studies have shown favour able results 261 , no clinical trials to date have demon strated the benefit of edifoligide for prevention of VGF. Edifoligide has been studied in the PREVENT trials. The PREVENT I study, a pilot study in patients (n = 41) undergoing PABG surgery, reported that edifoligide is safe, feasible, and could achieve sequencespecific inhib ition of cellcycle gene expression and DNA rep lication 262 . The PREVENT III and PREVENT IV trials were initiated to evaluate the efficacy and safety of edifo ligide for the prevention of VGF at 1 year after sur gery in patients undergoing PABG surgery (n = 1,400) or CABG surgery (n = 3,000), respectively. Despite promising results of the first two trials, edifoligide was no more effective than placebo in preventing VGF in these two patient cohorts after 12-18 months 263 . Although the results of the PREVENT trials were dis appointing, they are the first clinical trials to evaluate the use of intraoperative gene therapy in prevent ing VGF. Whether or not edifoligide should be used to prevent VGF is still under debate and should be further investigated 263, 264 . Future potential preventive strategies Gene therapy. Gene therapy has emerged as a poten tial therapy for the treatment and prevention of VGF. Saphenous vein grafts are ideally suited for gene therapy because they can be genetically modified ex vivo during the surgical procedure and before grafting 265 . Direct local delivery of recombinant viral vectors is possible and the risk of systemic exposure can be reduced 266 . Preclinical studies on a number of genetransfer strategies using specific genes delivered intraoperatively have been effec tive in either preventing intimal hyperplasia by limiting SMC proliferation or inflammation, or in improving endothelial function 128, 130, 134, 267 . Although these experi mental approaches have not been consistently successful, the practical benefits of gene therapy in vein grafts make it a promising technique, and hopefully these promis ing preclinical trials results can translated into clinical applications in due course 22, 261 .
External stenting. External stenting is another prom ising technique for the prevention of VGF. The use of external stents significantly reduced intimal hyperplasia in animal models, as discussed previously. In theory, external stenting should reduce wall tension, reduce stretching of endothelial cells, and function as a protec tive outer layer 268 . Despite the promising results obtained in experimental studies, the results from clinical stud ies were less positive. Graft patency rates were low after external stenting (6-19 months after surgery) [269] [270] [271] , probably owing to the stent size and material used, and the use of fibrin glue. Fibrin glue was used to attach the external stent to the outer layer of the vein graft; its use is no longer recommended as it has been associated with chronic inflammation and VGF 272 . In the past year, more promising results of external stenting for the treatment of VGF have emerged. Ferrari et al. reported positive pre liminary clinical results using a newly designed external mesh device that could improve longterm graft dur ability 272 . Similarly, Taggart et al. showed reduced intimal hyperplasia with the use of external stenting 1 year after CABG surgery 268 . The material, stent size, and placement of the external stent is of critical importance 70 . Further studies are needed to investigate the effect of external stenting on graft patency rates after bypass surgery. The firstinhuman study with the aim of testing the prelim inary safety and efficacy of the Angioshield wrap, an external vein graft support device, is currently ongoing 273 .
Graft complications and aneurysms
Coronary vein graft aneurysms have been described incidentally since 1975; however, peripheral vein graft aneurysms have not yet been reported 274 . Vein graft aneu rysms might be asymptomatic, although symptoms can arise from associated complications such as distal embo lization into the grafted artery, vessel rupture, fistula formation on adjacent vascular compartments, or com pression of neighbouring structures. The mechanisms responsible for aneurysmal dilatation of the vein grafts are poorly understood, but atherosclerosis and inflam matory factors are known to contribute to weakening of collagen in the vessel wall 275 . A review of 209 cases of aortocoronary saphenous vein graft aneurysms showed that in 90% of patients, CABG surgery was performed >5 years before detection of the aneurysm 276 .
Treatment strategies
Treatment strategies for VGF consists of medical ther apy, thrombectomy, redo bypass graft surgery, or balloon angioplasty with or without stenting 4, 277 (FIG. 7) . The most appropriate treatment modality for each individual patient depends on severity of symptoms, presence and extent of ischaemia, and the relative benefits and risks involved (such as the patient's general condition and presence of patent arterial grafts). Repeat bypass graft revascular ization is associated with a fourfold higher mortality than primary CABG surgery 278, 279 . No consen sus has been reached on how to treat the diseased vein grafts during repeated surgical revascularization. Some surgeons prefer to leave them untouched to prevent distal embolization, and make a new distal anastomosis on the target artery. When the original distal anastomosis is still patent, the vein can be transected at that level and the new graft can be anastomosed at the site 279 . Other sur geons prefer to ligate the diseased vein graft, or to remove it completely. However, in redo bypass graft surgery, particu larly for peripheral grafts, the saphenous vein is no longer available and other graft materials need to be used. Balloon angioplasty alone has proven to be effica cious for the treatment of VGF, although high rates of restenosis and major adverse events have been reported for both CABG surgery and PABG surgery 280, 281 . Mechanical embolic protection devices are useful dur ing balloon angioplasty of vein grafts for the preven tion of distal embolization 282, 283 . In addition, stents are known to reduce restenosis dramatically 284 . The SAVED trial 285 was the first study to compare balloon angioplasty with baremetal stents (BMS) on clinical outcomes in patients with obstructive disease of saphenous vein grafts. BMS reduced the need for revascularization of the target lesion and reduced major cardiac events com pared with balloon angioplasty 285 . Inconsistent results have been reported for the use of balloon angioplasty alone or balloon angioplasty with either BMS or DES in the treatment of VGF after PABG surgery or CABG surgery 280, [286] [287] [288] . No specific recommendations have been made by either the ESC or the AHA guidelines for revascularization after CABG surgery and PABG surgery 4, [19] [20] [21] . However, in the clinical setting of CABG surgery, balloon angioplasty with DES is the most fre quently used technique, and has been shown to be a safe and effective treatment for patients with failing saphenous vein grafts 289 . Vein graft interventions are riskprone procedures that are associated with poor longterm prognosis; however, the use of these techniques is unavoidable. The preferred percutaneous revascularization strategy of uncomplicated stenotic grafts is balloon angioplasty with DES in combination with optimal medical ther apy (such as antiplatelet therapy) and distal protection devices, when applicable 283 . Repeat bypass graft surgery might be the preferred option for old or diffusely dis eased venous grafts instead of percutaneous revascular ization. The optimal revascularization strategy should ultimately take into account patientspecific and procedurerelated factors.
Future perspectives
The barriers to finding a real breakthrough in treatment of VGF are attributable to the multifactorial nature of the processes involved in VGF and the frequently observed comorbidities in the patients with VGF. Mimicking this complex process using in vitro cultured human saphen ous vein segments is challenging 25, 130, 152, 290 . In this respect, animal models of VGF that suffer from comorbidities such as hypercholesterolaemia or diabetes are crucial for research 25, 291 . Interestingly, despite the major advances in genetic analysis of cardiovascular disease and predictive values of singlenucleotide poly morphism analysis for assessment of cardiovascular risk, no other genetic fac tors besides p27Kip1 have yet been found to be linked to increased risk of VGF 252, 292 . New methods for predict ing adaptations, remodelling, and even failure of vein grafts via a dynamic system that takes into account shear stress have been described 293, 294 . Furthermore, advances in imaging technologies such as optical coherence tomography will lead to less invasive analysis of vein graft remodelling and will provide more insight in the progression of VGF in patients after CABG surgery and PABG surgery 295 .
Conclusions
Vein graft surgery is one of the preferred surgical treat ment options for occlusive arterial disease. Although the use of vein grafts has diminished over the past few years and has been replaced by arterial grafts and balloon angio plasty, a substantial number of patients still require one or more vein grafts. Therefore, the issue of low patency rates owing to VGF needs urgent attention. Given their antiinflammatory properties and capacity to reduce plasma cholesterol levels, stat ins are recommended for the prevention of VGF. New therapies for the treatment of VGF, such as gene ther apy and external stenting are promising, but require more research. Although the PREVENT studies did not show increased patency rates with the use of E2F oligo nucleotide decoys as initially hypothesized, the results provided much insight in the development of VGF. The vein graft harvesting technique, duration of the surgery, graft handling, and the size and condition of the conduit and target vessel are all predictors of VGF. Preclinical and histopathological studies of human vein grafts fur ther demonstrate that constrictive remodelling, intimal hyperplasia formation, and unstable atherosclerotic lesions contribute to longterm VGF. These studies have shown that inflammatory components, especially those from the innate immune system, are crucial in all stages of vein graft development and failure, and have thus sug gested targeting inflammatory mediators for treatment of VGF. Furthermore, VGF can also be treated by pre venting endothelial cell damage, stimulating endothelial regrowth, and inhibiting SMC migration and prolifer ation. Additional studies are required to unravel the full potential of these treatment targets in preventing VGF and optimizing arterialization, and identifying the best revascularization strategies for failing grafts.
